Movement Alert｜Alebund Pharmaceuticals-B Rises 5.07% in Regular Trading, Post-IPO Recovery Extends on Institutional Backing and NDA Progress

Market Focus07-08

On July 8, Alebund Pharmaceuticals-B rose 5.07% in regular trading, trading at 31.3 HKD/share, with turnover of approximately 4 million HKD.

The stock continues its short-term recovery trajectory following significant post-IPO volatility. After listing on June 29 at an issue price of 22.6 HKD and surging over 103% on debut, the stock experienced a sharp pullback earlier this month. On the news front, GIC Private Limited and LAV Asset Management collectively acquired over 1.32 million shares on listing day, investing approximately 58.72 million HKD. GIC's stake rose to 7.09% while LAV's reached 7.20%, signaling long-term institutional confidence in the company's value.

Fundamentally, the company's core product AP301, an oral phosphate binder for hyperphosphatemia, has completed China Phase III registration trials and is expected to submit a New Drug Application imminently, placing the company within a 12-to-24-month window to commercialization.

Alebund Pharmaceuticals, founded in 2018, is a global biopharmaceutical company focused on kidney diseases, with a diversified pipeline covering hyperphosphatemia, renal anemia, IgA nephropathy, and diabetic kidney disease.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment